DZ2083A1 - Trihydrate de méthanesulfonate de (1s,2s)-1-(4-hydroxyphényl)-2-(4-hydroxy-4-phénylpipéridine-1-yl)-1-propanol, procédé pour sa préparation et composition pharmaceutique le contenant. - Google Patents

Trihydrate de méthanesulfonate de (1s,2s)-1-(4-hydroxyphényl)-2-(4-hydroxy-4-phénylpipéridine-1-yl)-1-propanol, procédé pour sa préparation et composition pharmaceutique le contenant.

Info

Publication number
DZ2083A1
DZ2083A1 DZ960127A DZ960127A DZ2083A1 DZ 2083 A1 DZ2083 A1 DZ 2083A1 DZ 960127 A DZ960127 A DZ 960127A DZ 960127 A DZ960127 A DZ 960127A DZ 2083 A1 DZ2083 A1 DZ 2083A1
Authority
DZ
Algeria
Prior art keywords
phenylpiperidine
hydroxyphenyl
hydroxy
preparation
pharmaceutical composition
Prior art date
Application number
DZ960127A
Other languages
English (en)
Inventor
Marta Maria Andino
Terry Gene Sinay
Eugene Fred Fiese
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DZ2083A1 publication Critical patent/DZ2083A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
DZ960127A 1995-08-11 1996-08-07 Trihydrate de méthanesulfonate de (1s,2s)-1-(4-hydroxyphényl)-2-(4-hydroxy-4-phénylpipéridine-1-yl)-1-propanol, procédé pour sa préparation et composition pharmaceutique le contenant. DZ2083A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US223895P 1995-08-11 1995-08-11

Publications (1)

Publication Number Publication Date
DZ2083A1 true DZ2083A1 (fr) 2002-10-23

Family

ID=21699847

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ960127A DZ2083A1 (fr) 1995-08-11 1996-08-07 Trihydrate de méthanesulfonate de (1s,2s)-1-(4-hydroxyphényl)-2-(4-hydroxy-4-phénylpipéridine-1-yl)-1-propanol, procédé pour sa préparation et composition pharmaceutique le contenant.

Country Status (41)

Country Link
US (1) US6008233A (fr)
EP (1) EP0843661B1 (fr)
JP (1) JP3099072B2 (fr)
KR (1) KR100291882B1 (fr)
CN (2) CN1198739A (fr)
AP (1) AP755A (fr)
AR (1) AR004676A1 (fr)
AT (1) ATE215072T1 (fr)
AU (1) AU710984B2 (fr)
BG (1) BG63678B1 (fr)
BR (1) BR9610766A (fr)
CA (1) CA2228752C (fr)
CO (1) CO4750830A1 (fr)
CZ (1) CZ296236B6 (fr)
DE (1) DE69620191T2 (fr)
DK (1) DK0843661T3 (fr)
DZ (1) DZ2083A1 (fr)
ES (1) ES2170857T3 (fr)
GT (1) GT199600051A (fr)
HR (1) HRP960372B1 (fr)
HU (1) HUP9802862A3 (fr)
IL (1) IL122649A (fr)
IS (1) IS1945B (fr)
MA (1) MA23957A1 (fr)
NO (1) NO310458B1 (fr)
NZ (1) NZ309134A (fr)
OA (1) OA10664A (fr)
PE (1) PE4898A1 (fr)
PL (1) PL185603B1 (fr)
PT (1) PT843661E (fr)
RO (1) RO120134B1 (fr)
RS (1) RS49521B (fr)
RU (1) RU2140910C1 (fr)
SA (1) SA96170171B1 (fr)
SK (1) SK284209B6 (fr)
TN (1) TNSN96104A1 (fr)
TR (1) TR199800208T1 (fr)
TW (1) TW495502B (fr)
UA (1) UA59341C2 (fr)
WO (1) WO1997007098A1 (fr)
ZA (1) ZA966760B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2139857C1 (ru) * 1994-08-18 1999-10-20 Пфайзер Инк. Производные 3-(пиперидинил-1)-хроман-4,7-диола и 1-(4-гидроксифенил)-2-(пиперидинил-1)-алканола, фармацевтическая композиция и способ связывания nmda рецептора
CN1198739A (zh) * 1995-08-11 1998-11-11 美国辉瑞有限公司 (1s,2s)－1－(4－羟基苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇甲磺酸盐三水合物
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU3676100A (en) * 1999-04-09 2000-11-14 Mochida Pharmaceutical Co., Ltd. Remedies for neuropathic pain
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
YU27701A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)1-propanola
YU27801A (sh) 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola i korisnih intermedijera
CA2413762A1 (fr) * 2000-08-16 2002-02-21 Pharmacia & Upjohn Company Composes pour le traitement de troubles toxicomanogenes
EP1186303A3 (fr) * 2000-09-06 2003-12-10 Pfizer Products Inc. Combinaisons pharmaceutiques pour le traitement des accidents cerebrovasculaires, contenant un facteur inhibitant la neutrophile et un antagoniste selectif du NMDA-NR2B
EP1674087A1 (fr) 2000-10-02 2006-06-28 Pfizer Products Inc. Utilisation prophylactique d'antagonistes des récepteurs du N-méthyl-D-aspartate (NMDA)
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
KR100956990B1 (ko) * 2001-10-19 2010-05-11 토야마 케미칼 컴퍼니 리미티드 알킬에테르유도체 또는 그 염
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
CN101346357B (zh) 2005-10-25 2014-04-02 盐野义制药株式会社 氨基二氢噻嗪衍生物
EP2151435A4 (fr) 2007-04-24 2011-09-14 Shionogi & Co Composition pharmaceutique pour le traitement de la maladie d'alzheimer
BRPI0811034A2 (pt) 2007-04-24 2014-12-09 Shionogi & Co Derivados de aminodi-hidrotiazina substituídos com um grupo cíclico e seus usos e composições farmacêuticas
CA2727859C (fr) 2008-06-13 2016-11-01 Shionogi & Co., Ltd. DERIVE HETEROCYCLIQUE CONTENANT DU SOUFRE AYANT UNE ACTIVITE INHIBANT LA ß-SECRETASE
WO2010047372A1 (fr) 2008-10-22 2010-04-29 塩野義製薬株式会社 2-aminopyridin-4-one et dérivé de 2-aminopyridine dont l'activité inhibe la bace1
JPWO2011071135A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 オキサジン誘導体
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
EP2634188A4 (fr) 2010-10-29 2014-05-07 Shionogi & Co Dérivé d'aminodihydropyrimidine fusionnée
EP2703399A4 (fr) 2011-04-26 2014-10-15 Shionogi & Co Dérivé d'oxazine et inhibiteur de bace 1 le contenant
JP2016501827A (ja) 2012-10-24 2016-01-21 塩野義製薬株式会社 Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
JP6612331B2 (ja) 2014-09-15 2019-11-27 リューゲン ホールディングス （ケイマン） リミテッド Ｎｒ２ｂ ｎｍｄａ受容体アンタゴニストとしてのピロロピリミジン誘導体
US20180271869A1 (en) * 2014-09-22 2018-09-27 Jie Liu Treatment of anxiety disorders and autism spectrum disorders
US10221182B2 (en) 2015-02-04 2019-03-05 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
EP3303323B1 (fr) 2015-06-01 2020-01-08 Rugen Holdings (Cayman) Limited Composés hétérocycliques 3,3-difluoropipéridine carbamate utilisés en tant qu'antagonistes des récepteurs nmda nr2b
US11000526B2 (en) 2016-11-22 2021-05-11 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
WO1990014087A1 (fr) * 1989-05-17 1990-11-29 Pfizer Inc. Derives de 2-piperidino-1-alcanol en tant qu'agents antiischemiques
RU2139857C1 (ru) * 1994-08-18 1999-10-20 Пфайзер Инк. Производные 3-(пиперидинил-1)-хроман-4,7-диола и 1-(4-гидроксифенил)-2-(пиперидинил-1)-алканола, фармацевтическая композиция и способ связывания nmda рецептора
CN1198739A (zh) * 1995-08-11 1998-11-11 美国辉瑞有限公司 (1s,2s)－1－(4－羟基苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇甲磺酸盐三水合物

Also Published As

Publication number Publication date
BG63678B1 (bg) 2002-09-30
US6008233A (en) 1999-12-28
JP3099072B2 (ja) 2000-10-16
DE69620191D1 (de) 2002-05-02
TNSN96104A1 (fr) 2005-03-15
BR9610766A (pt) 1999-07-13
CN1615861A (zh) 2005-05-18
EP0843661A1 (fr) 1998-05-27
ATE215072T1 (de) 2002-04-15
NZ309134A (en) 1999-09-29
SK284209B6 (en) 2004-11-03
AR004676A1 (es) 1999-03-10
CN1198739A (zh) 1998-11-11
AP755A (en) 1999-08-02
AU5908496A (en) 1997-03-12
PL325050A1 (en) 1998-07-06
IS4643A (is) 1997-12-30
RO120134B1 (ro) 2005-09-30
YU46196A (sh) 1999-07-28
UA59341C2 (uk) 2003-09-15
SK16698A3 (en) 1999-06-11
BG102289A (en) 1998-09-30
AU710984B2 (en) 1999-10-07
TW495502B (en) 2002-07-21
HRP960372B1 (en) 2003-04-30
IS1945B (is) 2004-08-13
NO310458B1 (no) 2001-07-09
CA2228752A1 (fr) 1997-02-27
IL122649A (en) 2001-08-26
EP0843661B1 (fr) 2002-03-27
AP9600856A0 (en) 1996-10-31
KR19990036321A (ko) 1999-05-25
NO980574D0 (no) 1998-02-10
TR199800208T1 (fr) 1998-05-21
JPH10510552A (ja) 1998-10-13
MX9801149A (es) 1998-05-31
PT843661E (pt) 2002-07-31
KR100291882B1 (ko) 2001-10-26
OA10664A (en) 2000-11-06
HUP9802862A2 (hu) 1999-04-28
MA23957A1 (fr) 1997-04-01
HRP960372A2 (en) 1998-04-30
CO4750830A1 (es) 1999-03-31
PE4898A1 (es) 1998-03-16
DK0843661T3 (da) 2002-07-22
NO980574L (no) 1998-02-10
ZA966760B (en) 1998-02-09
RS49521B (sr) 2006-10-27
RU2140910C1 (ru) 1999-11-10
GT199600051A (es) 1997-12-26
WO1997007098A1 (fr) 1997-02-27
IL122649A0 (en) 1998-08-16
DE69620191T2 (de) 2002-07-18
PL185603B1 (pl) 2003-06-30
CZ39098A3 (cs) 1999-02-17
CA2228752C (fr) 2002-12-10
ES2170857T3 (es) 2002-08-16
SA96170171B1 (ar) 2006-05-20
CZ296236B6 (cs) 2006-02-15
HUP9802862A3 (en) 1999-05-28

Similar Documents

Publication Publication Date Title
DZ2083A1 (fr) Trihydrate de méthanesulfonate de (1s,2s)-1-(4-hydroxyphényl)-2-(4-hydroxy-4-phénylpipéridine-1-yl)-1-propanol, procédé pour sa préparation et composition pharmaceutique le contenant.
DZ2128A1 (fr) Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2045A1 (fr) Amides thérapeutiques, procédé pour leur préparation et compositions les contenant.
CH689805A8 (fr) Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
DZ2074A1 (fr) Formulation nouvelle contenant de la paroxétine, et procédé pour sa préparation.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2718136B1 (fr) Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26614A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr) Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2198A1 (fr) Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant.
DZ2172A1 (fr) Dérivés de triazole utiles on thérapeutique, procédé pour leur préparation et compositions les contenant.
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA26451A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26519A1 (fr) Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2155A1 (fr) Aazétidines, procédé pour leur préparation, et co mpositions pharmaceutiques les contenant.
MA26567A1 (fr) Trifluoromethylethers cycliques a fonction piperidinylaminomethule, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26582A1 (fr) Derives de thiazolidinedione nouveau, procede pour sa preparation et composition pharmaceutique le contenant
DZ2044A1 (fr) 5,6-Dihydro-9h-pyrazolo Ä3,4-cÜ-1,2,4-triazol Ä4,3-alphaÜpyridines tricycliques procédé pour leur préparation et compositions les contenant.
DZ2486A1 (fr) Nouveaux dérivés du triazole un procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2948A1 (fr) Dérivé d'indole nouveau, procédé pour sa préparation et compositions pharmaceutiques le contenant.
FR2717802B1 (fr) Nouveaux composés aromatiques, procédé pour leur préparation et compositions pharmaceutiques en contenant.
FR2691461B1 (fr) Dérivés de cycloheptimidazole, procédé pour les préparer et composition pharmaceutique et agents thérapeutiques les contenant.